Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia

Adriana Branchi, Anna M. Fiorenza, Adriana Torri, Fulvio Muzio, Cristina Berra, Emanuela Colombo, Elena Dalla Valle, Angelo Rovellini, Domenico Sommariva

Research output: Contribution to journalArticle

Abstract

Background: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20-80 mg/d). Data on the effects of lower doses of the 2 drugs on HDL-C levels are conflicting. Objective: The purpose of this study was to investigate the effects of simvastatin 20 mg/d and atorvastatin 10 mg/d on HDL-C levels in patients with hypercholesterolemia. Methods: Patients with primary hypercholesterolemia (total cholesterol [TC] >250 mg/dL) who were not taking any lipid-lowering agents and who were following a low-fat diet were randomized to receive 1 of 2 treatments: simvastatin 20 mg/d or atorvastatin 10 mg/d. Serum TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and HDL-C levels were measured using standard methods after 2 months of therapy. In a secondary analysis, lipids and lipoprotein cholesterol were measured after 1 year in patients who continued treatment. Results: Of the 240 patients enrolled (108 men and 132 women; age range, 23-77 years, mean [SEM] 56.7 [0.69]), 235 completed the study. After 2 months of therapy, TC, LDL-C, and serum TG levels decreased significantly versus baseline in both groups (P <0.001), with no significant differences between treatment groups. HDL-C levels increased by 9.0% (P <0.001 vs baseline) in the simvastatin group and by 4.3% (P <0.02) in the atorvastatin group. The difference between the 2 groups in the percentage increase in HDL-C was statistically significant (P <0.05). In 113 patients who continued treatment, HDL-C levels at 1 year were still significantly higher than baseline levels in the simvastatin group (6.3%, P = 0.034), but not in the atorvastatin group (2.8%, P = 0.587). Conclusions: The findings from this study suggest that the HDL-C-increasing effect of simvastatin 20 mg is significantly greater than that of atorvastatin 10 mg. Since increasing HDL-C levels is thought to lower the risk for atherosclerosis and coronary heart disease, these results warrant further investigation.

Original languageEnglish
Pages (from-to)851-857
Number of pages7
JournalClinical Therapeutics
Volume23
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Simvastatin
Hypercholesterolemia
HDL Cholesterol
Cholesterol
LDL Cholesterol
Triglycerides
Therapeutics
Lipids
Atorvastatin Calcium
Fat-Restricted Diet
Serum
Coronary Disease
Atherosclerosis

Keywords

  • Atorvastatin
  • High-density lipoprotein cholesterol
  • Serum lipids
  • Simvastatin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia. / Branchi, Adriana; Fiorenza, Anna M.; Torri, Adriana; Muzio, Fulvio; Berra, Cristina; Colombo, Emanuela; Valle, Elena Dalla; Rovellini, Angelo; Sommariva, Domenico.

In: Clinical Therapeutics, Vol. 23, No. 6, 2001, p. 851-857.

Research output: Contribution to journalArticle

Branchi, Adriana ; Fiorenza, Anna M. ; Torri, Adriana ; Muzio, Fulvio ; Berra, Cristina ; Colombo, Emanuela ; Valle, Elena Dalla ; Rovellini, Angelo ; Sommariva, Domenico. / Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia. In: Clinical Therapeutics. 2001 ; Vol. 23, No. 6. pp. 851-857.
@article{a01e5bf39b464ccca44ee46dd4f597bb,
title = "Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia",
abstract = "Background: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20-80 mg/d). Data on the effects of lower doses of the 2 drugs on HDL-C levels are conflicting. Objective: The purpose of this study was to investigate the effects of simvastatin 20 mg/d and atorvastatin 10 mg/d on HDL-C levels in patients with hypercholesterolemia. Methods: Patients with primary hypercholesterolemia (total cholesterol [TC] >250 mg/dL) who were not taking any lipid-lowering agents and who were following a low-fat diet were randomized to receive 1 of 2 treatments: simvastatin 20 mg/d or atorvastatin 10 mg/d. Serum TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and HDL-C levels were measured using standard methods after 2 months of therapy. In a secondary analysis, lipids and lipoprotein cholesterol were measured after 1 year in patients who continued treatment. Results: Of the 240 patients enrolled (108 men and 132 women; age range, 23-77 years, mean [SEM] 56.7 [0.69]), 235 completed the study. After 2 months of therapy, TC, LDL-C, and serum TG levels decreased significantly versus baseline in both groups (P <0.001), with no significant differences between treatment groups. HDL-C levels increased by 9.0{\%} (P <0.001 vs baseline) in the simvastatin group and by 4.3{\%} (P <0.02) in the atorvastatin group. The difference between the 2 groups in the percentage increase in HDL-C was statistically significant (P <0.05). In 113 patients who continued treatment, HDL-C levels at 1 year were still significantly higher than baseline levels in the simvastatin group (6.3{\%}, P = 0.034), but not in the atorvastatin group (2.8{\%}, P = 0.587). Conclusions: The findings from this study suggest that the HDL-C-increasing effect of simvastatin 20 mg is significantly greater than that of atorvastatin 10 mg. Since increasing HDL-C levels is thought to lower the risk for atherosclerosis and coronary heart disease, these results warrant further investigation.",
keywords = "Atorvastatin, High-density lipoprotein cholesterol, Serum lipids, Simvastatin",
author = "Adriana Branchi and Fiorenza, {Anna M.} and Adriana Torri and Fulvio Muzio and Cristina Berra and Emanuela Colombo and Valle, {Elena Dalla} and Angelo Rovellini and Domenico Sommariva",
year = "2001",
doi = "10.1016/S0149-2918(01)80073-4",
language = "English",
volume = "23",
pages = "851--857",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia

AU - Branchi, Adriana

AU - Fiorenza, Anna M.

AU - Torri, Adriana

AU - Muzio, Fulvio

AU - Berra, Cristina

AU - Colombo, Emanuela

AU - Valle, Elena Dalla

AU - Rovellini, Angelo

AU - Sommariva, Domenico

PY - 2001

Y1 - 2001

N2 - Background: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20-80 mg/d). Data on the effects of lower doses of the 2 drugs on HDL-C levels are conflicting. Objective: The purpose of this study was to investigate the effects of simvastatin 20 mg/d and atorvastatin 10 mg/d on HDL-C levels in patients with hypercholesterolemia. Methods: Patients with primary hypercholesterolemia (total cholesterol [TC] >250 mg/dL) who were not taking any lipid-lowering agents and who were following a low-fat diet were randomized to receive 1 of 2 treatments: simvastatin 20 mg/d or atorvastatin 10 mg/d. Serum TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and HDL-C levels were measured using standard methods after 2 months of therapy. In a secondary analysis, lipids and lipoprotein cholesterol were measured after 1 year in patients who continued treatment. Results: Of the 240 patients enrolled (108 men and 132 women; age range, 23-77 years, mean [SEM] 56.7 [0.69]), 235 completed the study. After 2 months of therapy, TC, LDL-C, and serum TG levels decreased significantly versus baseline in both groups (P <0.001), with no significant differences between treatment groups. HDL-C levels increased by 9.0% (P <0.001 vs baseline) in the simvastatin group and by 4.3% (P <0.02) in the atorvastatin group. The difference between the 2 groups in the percentage increase in HDL-C was statistically significant (P <0.05). In 113 patients who continued treatment, HDL-C levels at 1 year were still significantly higher than baseline levels in the simvastatin group (6.3%, P = 0.034), but not in the atorvastatin group (2.8%, P = 0.587). Conclusions: The findings from this study suggest that the HDL-C-increasing effect of simvastatin 20 mg is significantly greater than that of atorvastatin 10 mg. Since increasing HDL-C levels is thought to lower the risk for atherosclerosis and coronary heart disease, these results warrant further investigation.

AB - Background: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20-80 mg/d). Data on the effects of lower doses of the 2 drugs on HDL-C levels are conflicting. Objective: The purpose of this study was to investigate the effects of simvastatin 20 mg/d and atorvastatin 10 mg/d on HDL-C levels in patients with hypercholesterolemia. Methods: Patients with primary hypercholesterolemia (total cholesterol [TC] >250 mg/dL) who were not taking any lipid-lowering agents and who were following a low-fat diet were randomized to receive 1 of 2 treatments: simvastatin 20 mg/d or atorvastatin 10 mg/d. Serum TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and HDL-C levels were measured using standard methods after 2 months of therapy. In a secondary analysis, lipids and lipoprotein cholesterol were measured after 1 year in patients who continued treatment. Results: Of the 240 patients enrolled (108 men and 132 women; age range, 23-77 years, mean [SEM] 56.7 [0.69]), 235 completed the study. After 2 months of therapy, TC, LDL-C, and serum TG levels decreased significantly versus baseline in both groups (P <0.001), with no significant differences between treatment groups. HDL-C levels increased by 9.0% (P <0.001 vs baseline) in the simvastatin group and by 4.3% (P <0.02) in the atorvastatin group. The difference between the 2 groups in the percentage increase in HDL-C was statistically significant (P <0.05). In 113 patients who continued treatment, HDL-C levels at 1 year were still significantly higher than baseline levels in the simvastatin group (6.3%, P = 0.034), but not in the atorvastatin group (2.8%, P = 0.587). Conclusions: The findings from this study suggest that the HDL-C-increasing effect of simvastatin 20 mg is significantly greater than that of atorvastatin 10 mg. Since increasing HDL-C levels is thought to lower the risk for atherosclerosis and coronary heart disease, these results warrant further investigation.

KW - Atorvastatin

KW - High-density lipoprotein cholesterol

KW - Serum lipids

KW - Simvastatin

UR - http://www.scopus.com/inward/record.url?scp=0034987894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034987894&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(01)80073-4

DO - 10.1016/S0149-2918(01)80073-4

M3 - Article

C2 - 11440285

AN - SCOPUS:0034987894

VL - 23

SP - 851

EP - 857

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -